This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Neovasc Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Feb 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:G5Z - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2023	10	-23	N/A	N/A	1
12/31/2022	4	-41	-25	-25	N/A
9/30/2022	3	-34	-24	-24	N/A
6/30/2022	3	-33	-25	-25	N/A
3/31/2022	3	-33	-26	-25	N/A
12/31/2021	3	-25	-27	-27	N/A
9/30/2021	2	-23	-30	-29	N/A
6/30/2021	2	-26	-31	-31	N/A
3/31/2021	2	-27	-32	-31	N/A
12/31/2020	2	-29	-30	-29	N/A
9/30/2020	2	-37	-29	-29	N/A
6/30/2020	2	-33	-27	-27	N/A
3/31/2020	2	-31	-25	-25	N/A
12/31/2019	2	-35	-24	-24	N/A
9/30/2019	2	-11	-24	-24	N/A
6/30/2019	2	-20	-23	-23	N/A
3/31/2019	2	-61	-24	-24	N/A
12/31/2018	2	-108	-23	-23	N/A
9/30/2018	2	-125	-141	-141	N/A
6/30/2018	3	-115	-140	-140	N/A
3/31/2018	4	-71	-138	-138	N/A
12/31/2017	5	-22	-139	-139	N/A
9/30/2017	7	19	-22	-21	N/A
6/30/2017	9	-5	-29	-28	N/A
3/31/2017	9	-83	-36	-35	N/A
12/31/2016	10	-86	-40	-40	N/A
9/30/2016	9	-131	N/A	-39	N/A
6/30/2016	8	-110	N/A	-35	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if G5Z's forecast earnings growth is above the savings rate (0.2%).

Ertrag vs. Markt: Insufficient data to determine if G5Z's earnings are forecast to grow faster than the German market

Hohe Wachstumserträge: Insufficient data to determine if G5Z's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if G5Z's revenue is forecast to grow faster than the German market.

Hohe Wachstumseinnahmen: Insufficient data to determine if G5Z's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if G5Z's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Neovasc Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

Neovasc Announces Progress on COSIRA-II Clinical Trial

Third quarter 2022 earnings released: US$3.00 loss per share (vs US$2.79 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Neovasc Inc. to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

Neovasc Inc. Announces Positive Clinical Data at Transcatheter Cardiovascular Therapeutics Conference and Provides Update on Mitral Valve Program

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

Independent Director recently bought €76k worth of stock

Second quarter 2022 earnings released: US$3.29 loss per share (vs US$3.35 loss in 2Q 2021)

Neovasc Inc. to Report Q2, 2022 Results on Aug 11, 2022

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

First quarter 2022 earnings released: US$3.75 loss per share (vs US$1.11 loss in 1Q 2021)

Neovasc Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Neovasc Inc. to Report Q4, 2021 Results on Mar 10, 2022

Neovasc Inc., Annual General Meeting, Apr 12, 2022

German Institute for the Hospital Remuneration System Awards Neovasc, Inc.'s Reducer™ NUB Status 1 Designation for 2022

Neovasc Inc. Announces the Publication of Cost-Effectiveness Studies Supporting the Use of the Neovasc Reducer

Neovasc Inc. Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Neovasc Inc. Announces Case Series of First U.S. Reducer Implants Published in Peer-Reviewed Journal

Neovasc Announces First Patient Enrollment in Cosira-II Trial

Chief Operating Officer recently bought €70k worth of stock

The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)

Independent Director recently bought €65k worth of stock

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)

Independent Director recently bought €73k worth of stock

Neovasc Inc Provides Corporate Update

Neovasc Reducer System Receives First National Reimbursement in Europe

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. Provides Update on German Litigation

Neovasc Announces First Patient Enrollment in COSIMA Trial

First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)

Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)

Revenue misses expectations

Neovasc Inc. to Report Q4, 2020 Results on Mar 11, 2021

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

New 90-day high: €1.25

American Medical Association Issues New CPT Code for Neovasc Reducer Procedure

New 90-day high: €1.10

Neovasc Inc. Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)

Zhang Investor Law Alerts Investors to Upcoming Deadline in Securities Class Action Lawsuit Against Neovasc Inc

Pomerantz LLP Announces A Class Action Lawsuit Filed Against Neovasc Inc. and Certain of Its Officers

Neovasc Announces First Neovasc Reducer Implants in France

Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $6.10681 million.

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

New 90-day low: €0.56

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Neovasc Inc

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. (NVCN) Investors

Pawar Law Group Announces A Securities Class Action Lawsuit Against Neovasc Inc

New 90-day low: €0.61

Third quarter 2020 earnings released: US$0.51 loss per share

Revenue beats expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Neovasc Inc

New 90-day low: €1.64

Neovasc, Inc. Treats 300 Patient in Germany with the Neovasc Reducer

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $12.581842 million.

New 90-day low - €1.90

Earnings released

Neovasc Inc. to Report Q2, 2020 Results on Aug 06, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken